Dr. Stevens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Paterson St
Clinical Academic Building Suite 5200a
New Brunswick, NJ 08901Phone+1 732-235-7217Fax+1 732-212-0713
Education & Training
Roger Williams Medical CenterFellowship, Rheumatology, 1985 - 1987
Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1982 - 1985
Case Western Reserve University School of MedicineClass of 1982
Certifications & Licensure
NJ State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis Start of enrollment: 2010 Dec 09
Publications & Presentations
PubMed
- 18 citationsCurrent Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.Gulen Hatemi, Yesim Ozguler, H. Direskeneli, Alfred Mahr, Ahmet Gül
The Journal of Rheumatology. 2015-12-01 - 111 citationsOptimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop.Jason W. Busse, Susan J. Bartlett, Maxime Dougados, Bradley C. Johnston, Gordon H. Guyatt
The Journal of Rheumatology. 2015-05-15 - 1884 citationsEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.Jonathan C. W. Edwards, Leszek Szczepanski, Jacek Szechiński, Anna Filipowicz-Sosnowska, Paul Emery
The New England Journal of Medicine. 2004-06-17
Press Mentions
CNTX-4975 Injection Improves OA-Associated Knee PainApril 12th, 2019
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s NeuromaFebruary 9th, 2017
Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration TechniquesJuly 29th, 2019
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
